What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP) , Electro Optic Systems (EOS) , First Graphene (FGR) , Envirosuite (EVS) , Bubs Australia (BUB) , Blue Energy (BLU) , BHP Group (BHP) , Alcidion Group (ALC) , a2 Milk (A2M) and 8common (8CO) .

ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free PAR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 1.81 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Paradigm Biopharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

PAR Stock News Headlines

April 19, 2024 | msn.com

Paradigm Signs ‘Fire Island’ & ‘How To Get Away With Murder’ Actor Conrad Ricamora

April 19, 2024 | msn.com

Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 17, 2024 | msn.com

Sheboygan jazz masterclass at Paradigm will feature Milwaukee Jazz Institute's managing director

April 9, 2024 | msn.com

WWE Star Damian Priest Signs With Paradigm (EXCLUSIVE)

April 9, 2024 | benzinga.com

Monad Labs Raises $225 Million in Funding Round Led by Paradigm

April 9, 2024 | sg.style.yahoo.com

10 best makan places in Paradigm Mall JB

April 4, 2024 | msn.com

Reggie Bush Signs With Paradigm Talent Agency In All Areas, Launches Production Company

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | msn.com

Merkle Achieves $1 Billion Valuation with Paradigm Leading Funding Surge

March 27, 2024 | msn.com

Paradigm Signs ‘Red, White & Royal Blue’ Breakout Taylor Zakhar Perez

March 20, 2024 | msn.com

Lit Agents Alysia Thomas, Kelsey Roberts Exit Paradigm

March 19, 2024 | uk.movies.yahoo.com

Paradigm Hires Verve Alums Bill Weinstein, Devon Schiff As Lit Agents

March 19, 2024 | msn.com

Bill Weinstein Joins Paradigm Talent Agency Following Verve Exit

March 19, 2024 | msn.com

Bill Weinstein & Paradigm At The Altar? – The Dish

March 18, 2024 | msn.com

Ocugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon

March 13, 2024 | finance.yahoo.com

Shift Paradigm acquires design and technology consultancy Principle Studios

March 11, 2024 | msn.com

Monad Labs in talks to raise more than $200 million round led by Paradigm, valuing the Jump Crypto–linked startup at $3 billion

February 29, 2024 | tmcnet.com

Paradigm by Puloli™ Announces Customers in Eagle Ford

February 27, 2024 | msn.com

Jaime King Signs With Paradigm

February 27, 2024 | msn.com

What’s in store for 2024: Paradigm Biopharmaceuticals

February 23, 2024 | tmcnet.com

Global Disinfection Robots Market Report 2024: Analysis of Funding and Investments for Developing Disinfection Robots

February 22, 2024 | yahoo.com

Paradigm Hires Kyle Jensen and Jamie Kaye-Phillips, Promotes Matthew Nutty, Taps Brian Neal for Napoli Management Group

February 20, 2024 | msn.com

ASX stocks striving to inject youthfulness into an aging world population

February 14, 2024 | bloomberg.com

Paradigm’s Famed ‘White-Hat’ Hacker Unites Peers Against Crypto Attacks

February 11, 2024 | finance.yahoo.com

Paradigm Biopharmaceuticals Limited (ASX:PAR) Is Expected To Breakeven In The Near Future

February 8, 2024 | morningstar.com

Paradigm Biopharmaceuticals Ltd PAR

See More Headlines

Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:PAR
CUSIP: N/A
CIK: N/A
Web: www.paradigmbiopharma.com
Phone: 61 3 9629 5566
Fax: N/A
Employees: 1,031
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,000,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -128.42%
Return on Assets: -72.47%

Debt

Debt-to-Equity Ratio: 0.86
Current Ratio: 3.83
Quick Ratio: 5.93

Sales & Book Value

Annual Sales: $79,224.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 6.44
Book Value: A$0.10 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 351,200,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.92

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Paul John Rennie BSc (Age 65)
Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman
Comp: $1.75M
Dr. Donna L. Skerrett M.D. (Age 67)
MS, Chief Medical Officer and Executive Director
Comp: $1.26M
Ms. Abby Macnish Niven B.Com.
B.Sc., C.F.A., Interim Company Secretary & Interim CFO
Dr. Ravi Krishnan
Chief Scientific Officer
Mr. Simon White
Director of Investor Relations
Dr. Michael Imperiale
Global Head of Drug Safety & MPS
Ms. Beverley Huttmann
Commercial Head
Ms. Michelle Coffey
Global Head of Regulatory Affairs
Dr. Mukesh Ahuja
Global Clinical Head of OA

Key Competitors

View All Competitors

Insiders

PAR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Paradigm Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO).

This page (ASX:PAR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial